Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03030001Phase 1Unknown

PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies

Role: lead

NCT02873442Phase 1Unknown

Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer

Role: lead

NCT02873416Phase 1Unknown

Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer

Role: lead

NCT02873520Phase 1Unknown

Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer

Role: lead

NCT02873390Phase 1Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

Role: lead

All 5 trials loaded